Pro-inflammatory cytokines and chemokine pathways

Pro-inflammatory cytokines and chemokine pathways constitute a sophisticated signaling network essential for initiating and regulating the host immune response to injury and infection (NIH, 2022). This system involves a diverse array of proteins, including interleukins (IL-1, IL-6), tumor necrosis factors (TNF), and chemotactic cytokines (chemokines), which bind to specific cell-surface receptors to trigger intracellular cascades such as the JAK-STAT or NF-kappaB pathways (Nature Reviews Immunology, 2018). In healthy states, these pathways facilitate the recruitment and activation of leukocytes to eliminate pathogens and promote tissue repair. However, chronic or excessive activation of these pathways is a primary driver of tissue damage in autoimmune disorders, such as rheumatoid arthritis and Crohn's disease, as well as in the systemic inflammatory response syndrome associated with severe infections (PubMed: 32324593). Pharmacological modulation of these pathways is a cornerstone of modern immunology, utilizing monoclonal antibodies to sequester ligands or small molecules to inhibit signal transduction. Because these pathways are integral to systemic immunity, therapeutic strategies must carefully balance the suppression of chronic inflammation with the preservation of essential host defense mechanisms (StatPearls, 2023).

Other names

Inflammatory cytokine signalingChemokine-mediated signaling pathwayPro-inflammatory cascadeCytokine-chemokine network

Therapeutic agents modulate these pathways through ligand neutralization (e.g., anti-TNF antibodies), competitive receptor antagonism (e.g., IL-1 receptor antagonists), or the inhibition of downstream intracellular signaling enzymes like Janus kinases (JAKs) to suppress the production and action of inflammatory mediators (StatPearls, 2023; PubMed: 31043915).